Actively Recruiting

Phase Not Applicable
Age: 50Years - 80Years
All Genders
NCT07168993

Evaluate the Clinical Performance of the Flow Cytometry - FlowPath Lung Test as a Sensitive and Specific Non-invasive Diagnostic of Sputum Samples to Identify/Detect the Presence of Lung Cancer in High-risk Individuals Who Have Existing Lung Nodules, 6 to <30 mm in Diameter, Determined by LDCT.

Led by bioAffinity Technologies Inc. · Updated on 2026-03-18

2063

Participants Needed

3

Research Sites

174 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Evaluate FlowPath Lung Diagnostic Test of Sputum Samples to Detect the Presence of Lung Cancer in High-risk Individuals Who Have Existing Lung Nodules, \>6 to \<30 mm in Diameter, Determined by LDCT.

CONDITIONS

Official Title

Evaluate the Clinical Performance of the Flow Cytometry - FlowPath Lung Test as a Sensitive and Specific Non-invasive Diagnostic of Sputum Samples to Identify/Detect the Presence of Lung Cancer in High-risk Individuals Who Have Existing Lung Nodules, 6 to <30 mm in Diameter, Determined by LDCT.

Who Can Participate

Age: 50Years - 80Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Able to give signed informed consent and comply with study requirements
  • Aged between 50 and 80 years
  • Current smoker with at least 20 pack-years smoking history or former smoker with at least 20 pack-years who quit within the past 15 years
  • Has a lung nodule between 6 and 30 mm in diameter found by CT scan
  • Nodule is new, increasing, or stable for 6 months or less
  • If multiple nodules, the most suspicious nodule is between 6 and 30 mm
  • Willing to provide a sputum sample for FlowPath Lung Test within 6 weeks of baseline CT scan
  • Willing to provide contact information for medical follow-up
Not Eligible

You will not qualify if you...

  • Unable to cough with enough force to produce a sputum sample
  • Dominant nodule is ground glass or part solid on CT scan
  • Has 5 or more nodules larger than 4 mm
  • Nodule is a distal endobronchial or perifissural nodule
  • Is immunosuppressed
  • Has rheumatoid arthritis
  • Had lung cancer in the past 5 years or any other cancer (except non-melanoma skin cancer) in past 2 years
  • Has angina with minimal exertion
  • Is currently pregnant or planning pregnancy during the study

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 3 locations

1

Clinical Research Associates of Central Pennsylvania

DuBois, Pennsylvania, United States, 15801

Actively Recruiting

2

Audie Murphy VA Medical Center

San Antonio, Texas, United States, 78234

Actively Recruiting

3

Brooke Army Medical Center

San Antonio, Texas, United States, 78234

Actively Recruiting

Loading map...

Research Team

X

Xavier T Reveles, MS, CG(ASCP)

CONTACT

S

Stacy K Stanek

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

DIAGNOSTIC

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Evaluate the Clinical Performance of the Flow Cytometry - FlowPath Lung Test as a Sensitive and Specific Non-invasive Diagnostic of Sputum Samples to Identify/Detect the Presence of Lung Cancer in High-risk Individuals Who Have Existing Lung Nodules, 6 to <30 mm in Diameter, Determined by LDCT. | DecenTrialz